Home  |  Product  |  Biosimilars
Biosimilars Biosimilars mean copy pharmaceutical products, of which bioequivalence is approved in terms of quality, efficacy and safety compared with original biopharmaceuticals developed and sold using biotechnology such as recombinant DNA and cell culture technology.

Patent expiry, patient and market demand, changes in government regulatory policies are factors that are re-shaping the market landscape that is favorable to biosimilars.
Introduction of biosimilar products to the global market should bring down the cost of medicine substantially for critical diseases and provide more therapeutic oppurtunities for patients.

Market environment

1. Korean market situation for the introduction of biosimilars